Filing Flows › Mirum Pharmaceuticals (MIRM) › Q3 2026 › vs Q3 2025
Mirum Pharmaceuticals (MIRM) Q3 2026 vs Q3 2025 (year over year)
Mirum Pharmaceuticals's revenue rose $52.7M (+40%) from $133M in Q3 2025 to $186M in Q3 2026. The biggest changes: Livmarli +$41.2M (+45%); Bile Acid Medicines +$11.5M (+28%).
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Livmarli | $133M | $92.2M | $41.2M | +45% |
| Bile Acid Medicines | $52.3M | $40.8M | $11.5M | +28% |
| Revenue | $186M | $133M | $52.7M | +40% |
| Other income, net | $19.5M | $40K | $19.5M | 488× |
| Net loss | $40.8M | −$2.9M | $43.7M | — |
| Costs & expenses | $246M | $133M | $113M | +85% |
| Operating costs | $245M | $130M | $115M | +88% |
| Income tax | $538K | −$262K | $800K | — |
| Research & development | $108M | $43.0M | $65.0M | +151% |
| SG&A | $88.9M | $61.9M | $27.0M | +44% |
| Other operating costs | $48.7M | $25.5M | $23.1M | +91% |
| Operating cash sources | $44.5M | −$15.5M | $60.0M | — |
| Depreciation & amortization | $6.9M | $6.1M | $827K | +14% |
| Share-based compensation | $33.3M | $18.1M | $15.2M | +84% |
| Cash used in operations | $4.3M | −$39.7M | $44.0M | — |
| Net loss absorbed | $40.8M | −$2.9M | $43.7M | — |
| Working capital & other | $3.7M | −$12.6M | $16.3M | — |
Questions
How much did Mirum Pharmaceuticals's revenue grow year over year in Q3 2026?
Mirum Pharmaceuticals's revenue rose $52.7M (+40%) from $133M in Q3 2025 to $186M in Q3 2026.
What drove Mirum Pharmaceuticals's revenue change in Q3 2026?
Livmarli +$41.2M (+45%); Bile Acid Medicines +$11.5M (+28%).